A lot of health data are generated outside the traditional clinical research setting. Analysing such Real-World Data (RWD) or Real-World Evidence (RWE) can provide valuable insights, for market strategy and health economic outcomes as well as for clinical research and drug development. Analyzing anonymized patient-level RWD can help to optimize clinical trial study designs and direct hospital site selection, which considerably reduces the time, cost and errors involved.
CMAST collaborates with healthcare data providers and masters RWD platform(s). With our top-class health data analytics expertise, we can offer game-changing insights allowing to better align your clinical R&D process to the real-world situation. Our medical expertise and specialist know-how in epidemiology, biostatistics, clinical R&D, pharmacovigilance and market access supports our clients in their endeavours to execute cost effective clinical research.